OncoMatch/Clinical Trials/NCT06071013
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Is NCT06071013 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Nintedanib, gefitinib, erlotinib, afatinib, osimertinib for non-small cell lung cancer.
Treatment: Nintedanib, gefitinib, erlotinib, afatinib, osimertinib — The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
Positive EGFR mutations are diagenesis
Required: PRKCD wild-type (nPKCδ expression not negative by IHC)
Participants have a known diagnosis of negative nPKCδ expression by immunohistochemistry (IHC) [excluded]
Disease stage
Required: Stage III, IV
Prior therapy
Must have received: egfr tyrosine kinase inhibitor (gefitinib, erlotinib, afatinib, osimertinib) — first-line
Cannot have received: egfr tyrosine kinase inhibitor
Exception: serious side effects
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify